Figure 5.
Clinical outcomes in patients receiving haploidentical HSCT with or without recombinant human TPO treatment. A, The neutrophil engraftment, platelet engraftment, and platelet recovery in patients with SAA receiving haploidentical HSCT with or without TPO administration. B, The neutrophil engraftment, platelet engraftment, and platelet recovery in patients with hematologic malignancies receiving haploidentical HSCT with or without TPO treatment. HSCT, hematopoietic stem cell transplantation; SSA, severe aplastic anemia; TPO, thrombopoietin